Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
Article
Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie et al. (2019). Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
. NEURO-ONCOLOGY, 21(4), 486-497. 10.1093/neuonc/noz002
Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie et al. (2019). Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
. NEURO-ONCOLOGY, 21(4), 486-497. 10.1093/neuonc/noz002